Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Pharmaceutical Executive
October issue detects source of success as pricing power, depending on company's ability to come in first with a new indication or offer compelling unique value proposition that payers will accept
NEW YORK, Oct. 17, 2013 /PRNewswire/ -- PHARMACEUTICAL EXECUTIVE, the biopharmaceutical industry's premier publication, highlights the 2013 Annual Audit of biopharmaceutical companies that deliver the most for their stockholders, as the cover story of its October issue.
"This year, it's all in the pricing, stupid," says William Looney, Pharmaceutical Executive's Editor-in-Chief.
And yet, as Looney points out, even that strategy is not a sure thing in this changing landscape. The 2013 Pharm Exec Audit winner, Novo Nordisk, just last month had its blockbuster diabetes drug Victoza fall victim when Express Scripts dropped it from its formulary in favor of an older drug.
The question then becomes how much longer can pricing power last in a U.S. market where just one Pharmacy Benefit Manager (PBM) controls 40 per cent of all drugs dispensed?
A monthly magazine and daily online publication, PHARMACEUTICAL EXECUTIVE, offers policy analysis and in-depth business coverage of the global biopharmaceutical, vaccine and medical device industries.
EDITOR WILLIAM LOONEY ON PHARMACEUTICAL EXECUTIVE'S OCTOBER 2013 INDUSTRY AUDIT COVER STORY
"True to form our October issue highlights a latent threat to Big Pharma: A behavioral mindset that may be best characterized as 'ageing in place.' It is what happens when businesses grow so large as to spawn their own internal weather patterns. One where markets are treated as inhabitants of an entirely different solar system-unnoticed, neglected and forgotten. Past successes founded on blockbuster sales model have led to an orgy of size and scale, which leads to an equally big question: Is this industry nimble enough for a new era where medicine is personal, science is targeted and the best new breakthroughs come in smaller packages?"
WILLIAM LOONEY adds: "Implicit in the Audit is that biopharma is becoming a classic mature industry, characterized by slower revenue growth, intense market competition, and eroding margins. The message is clear: If your company's response to all this is to 'age in place,' then you won't even be on our Audit in five years."
For more information contact: William Looney: (212) 951-6735
Read more news from Pharmaceutical Executive.
©2012 PR Newswire. All Rights Reserved.